Literature DB >> 19197327

Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta.

D H Meijer1, C A Maguire, S G LeRoy, M Sena-Esteves.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive type of all primary brain tumors, with an overall median survival <1 year after diagnosis. Despite introduction of multimodal treatment approaches, the prognosis has not improved significantly over the past 50 years. In this study we investigated the effect of intracerebroventricular (ICV) injection of an adeno-associated virus (AAV) vector encoding human interferon-beta (AAV-hIFN-beta) on glioblastoma growth. Recently, we found that peritumoral parenchymal transduction with an AAV-hIFN-beta was exceptionally efficient in eradicating GBM brain tumors. However, the extensive infiltration and migration displayed by glioblastoma cells in patients may leave a significant number of tumor cells outside a local therapeutic zone created by intraparenchymal delivery of AAV vectors. Here we show that pretreatment of mice by ICV infusion of an AAV-IFN-beta completely prevents tumor growth in an orthotopic model of GBM. Furthermore, ICV infusion of AAV-IFN-beta into mice bearing preestablished U87 intracranial tumors improved their survival compared to mice infused through the same route with a control AAV vector. These data suggest that ICV injection of AAV vectors encoding antitumor proteins is a promising approach deserving further consideration for the treatment of GBM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197327      PMCID: PMC2946391          DOI: 10.1038/cgt.2009.8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  29 in total

1.  Identification of genes selectively regulated by IFNs in endothelial cells.

Authors:  Stefano Indraccolo; Ulrich Pfeffer; Sonia Minuzzo; Giovanni Esposito; Valeria Roni; Susanna Mandruzzato; Nicoletta Ferrari; Luca Anfosso; Raffaella Dell'Eva; Douglas M Noonan; Luigi Chieco-Bianchi; Adriana Albini; Alberto Amadori
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

2.  Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.

Authors:  M L D Broekman; L A Comer; B T Hyman; M Sena-Esteves
Journal:  Neuroscience       Date:  2006-01-18       Impact factor: 3.590

Review 3.  New treatment strategies for malignant gliomas.

Authors:  Sith Sathornsumetee; Jeremy N Rich
Journal:  Expert Rev Anticancer Ther       Date:  2006-07       Impact factor: 4.512

4.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

Authors:  Krystof S Bankiewicz; John Forsayeth; Jamie L Eberling; Rosario Sanchez-Pernaute; Philip Pivirotto; John Bringas; Peter Herscovitch; Richard E Carson; William Eckelman; Bryan Reutter; Janet Cunningham
Journal:  Mol Ther       Date:  2006-07-07       Impact factor: 11.454

5.  Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.

Authors:  Patricia Dickson; Michael McEntee; Carole Vogler; Steven Le; Beth Levy; Maryn Peinovich; Stephen Hanson; Merry Passage; Emil Kakkis
Journal:  Mol Genet Metab       Date:  2007-02-26       Impact factor: 4.797

6.  Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Michael Chang; Jonathan D Cooper; David E Sleat; Seng H Cheng; James C Dodge; Marco A Passini; Peter Lobel; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-02-12       Impact factor: 11.454

7.  Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.

Authors:  Janet Cunningham; Philip Pivirotto; John Bringas; Brian Suzuki; Sharmila Vijay; Laura Sanftner; Marina Kitamura; Curtis Chan; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2008-06-03       Impact factor: 11.454

Review 8.  Angiogenesis in brain tumours.

Authors:  Rakesh K Jain; Emmanuelle di Tomaso; Dan G Duda; Jay S Loeffler; A Gregory Sorensen; Tracy T Batchelor
Journal:  Nat Rev Neurosci       Date:  2007-08       Impact factor: 34.870

9.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain.

Authors:  Cassia N Cearley; Luk H Vandenberghe; Michael K Parente; Erin R Carnish; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

10.  Interferon-gamma mRNA attenuates its own translation by activating PKR: a molecular basis for the therapeutic effect of interferon-beta in multiple sclerosis.

Authors:  Raymond Kaempfer
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

View more
  19 in total

1.  P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line.

Authors:  Marina Petersen Gehring; Talita Carneiro Brandão Pereira; Rafael Fernandes Zanin; Magali Carvalho Borges; Aroldo Braga Filho; Ana Maria Oliveira Battastini; Maurício Reis Bogo; Guido Lenz; Maria Martha Campos; Fernanda Bueno Morrone
Journal:  Purinergic Signal       Date:  2012-05-28       Impact factor: 3.765

Review 2.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 3.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

4.  Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.

Authors:  Masahide Matsuda; Keisuke Nimura; Takashi Shimbo; Toshimitsu Hamasaki; Tetsuya Yamamoto; Akira Matsumura; Yasufumi Kaneda
Journal:  J Neurooncol       Date:  2010-08-22       Impact factor: 4.130

5.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

6.  Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Authors:  I Zolotukhin; D Luo; Os Gorbatyuk; Be Hoffman; Kh Warrington; Rw Herzog; Jk Harrison; O Cao
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-29

Review 7.  Adeno-associated virus-mediated cancer gene therapy: current status.

Authors:  Jingfeng Luo; Yuxuan Luo; Jihong Sun; Yurong Zhou; Yajing Zhang; Xiaoming Yang
Journal:  Cancer Lett       Date:  2014-11-10       Impact factor: 8.679

8.  Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy.

Authors:  Yi Gong; Dakai Mu; Shilpa Prabhakar; Ann Moser; Patricia Musolino; JiaQian Ren; Xandra O Breakefield; Casey A Maguire; Florian S Eichler
Journal:  Mol Ther       Date:  2015-01-16       Impact factor: 11.454

9.  Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

Authors:  Guido Wollmann; Justin C Paglino; Patrick R Maloney; Sebastian A Ahmadi; Anthony N van den Pol
Journal:  Virology       Date:  2014-11-21       Impact factor: 3.616

10.  Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.

Authors:  Adrienn Volak; Stanley G LeRoy; Jeya Shree Natasan; David J Park; Pike See Cheah; Andreas Maus; Zachary Fitzpatrick; Eloise Hudry; Kelsey Pinkham; Sheetal Gandhi; Bradley T Hyman; Dakai Mu; Dwijit GuhaSarkar; Anat O Stemmer-Rachamimov; Miguel Sena-Esteves; Christian E Badr; Casey A Maguire
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.